There is essentially no subjective effect. Ezetimibe is a peripheral GI-acting drug with negligible CNS penetration. Users do not report any "feel" — no energy change, no mood change, no cognitive change. The only thing that changes is the lipid panel.

Onset: LDL-C begins dropping within 2 weeks; near-maximal effect by week 4. Steady-state achieved by week 4-6.

Peak effect: Stable from week 4-6 onward, indefinitely.

Taper: Stopping ezetimibe → LDL returns to baseline within 4-8 weeks as enterocyte NPC1L1 fully recovers and intestinal absorption normalizes.

Characteristic effects (most users):

• No felt effect. This is a feature, not a bug.
• Possible mild GI symptoms (loose stools, abdominal discomfort) for the first 1-2 weeks in a small fraction of users.
• Possible mild fatigue or myalgia (rare and usually attributable to concurrent statin).

• Tolerance buildup: None. NPC1L1 inhibition is durable; LDL-C reduction is sustained for years of continuous use without escape.
• Recommended cycle: None. Daily indefinite use is the standard.
• Reset protocol if needed: Not applicable. Discontinuation reverses effect within 4-8 weeks.
• Dependence: None.

Synergistic with

• Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin): Mechanism-level synergy. Statins induce NPC1L1 upregulation; ezetimibe blocks the resulting compensation. Standard of care for LDL-C targets that statin monotherapy doesn't reach. IMPROVE-IT and RACING are the proof.
• PCSK9 inhibitors (evolocumab, alirocumab): Cleanly additive — ezetimibe pushes hepatic LDL-receptor demand, PCSK9i prevents receptor degradation. Combined LDL drops can exceed 70%.
• Bempedoic acid: Both non-statin LDL-lowering paths; bempedoic acid hits ATP-citrate lyase upstream of HMG-CoA reductase. Combo (Nexlizet) is the standard non-statin combo.
• Plant sterols / stanols (dietary): Theoretical interference (both compete at NPC1L1) — historical concern, but clinical data shows ezetimibe still works; minor reduction in plant sterol absorption is actually a feature, not a bug.

Avoid stacking with

• Cyclosporine: Cyclosporine raises ezetimibe AUC ~3-12×. If unavoidable, monitor levels and use lowest effective dose. Not a Dylan concern.
• Cholestyramine / colesevelam (bile acid sequestrants): Bind ezetimibe in the gut and reduce absorption ~55-80%. If both are used, take ezetimibe ≥2 hours before or ≥4 hours after the sequestrant.
• Fibrates (fenofibrate, gemfibrozil): Modestly raise ezetimibe AUC; clinical concern is gallstone risk via altered bile composition. Use with caution and monitor; gemfibrozil specifically often avoided in combination.

Neutral / safe co-administration

• All Dylan stack components: NAC, citicoline, magnesium, fish oil, PS, D3+K2, beta-alanine, creatine, taurine, l-theanine, glycine, rhodiola, curcumin, vitamin C — all neutral.
• Modafinil, bromantane, semax, adamax, selank, cerebrolysin, ALCAR, apigenin, astaxanthin — all neutral.
• Tadalafil — neutral.
• Caffeine — neutral.

• Minimal CYP interaction. Ezetimibe is glucuronidated (UGT1A1, UGT1A3, UGT2B15) and undergoes enterohepatic recirculation; it is not a significant CYP3A4 / CYP2D6 / CYP2C9 substrate, inhibitor, or inducer. This is a major clinical advantage — interaction profile is short.
• Cyclosporine — bidirectional AUC increase (cyclosporine and ezetimibe each raise the other's exposure). Avoid or use with monitoring.
• Cholestyramine, colesevelam, colestipol — reduce ezetimibe absorption; spaced dosing required.
• Warfarin — small INR increases reported in some patients; monitor INR when starting.
• Fibrates (gemfibrozil, fenofibrate) — additive gallstone risk; gemfibrozil specifically raises ezetimibe AUC ~1.7×.
• No effect on glucose / insulin / HbA1c.
• No HPG-axis effect.
• Not on any WADA banned list — relevant only if Dylan ever competes in tested events.

• NPC1L1 polymorphisms: rare loss-of-function variants confer naturally low cholesterol absorption and lower LDL — these individuals get less benefit from ezetimibe (they're already partially in its target state) but also have lower baseline LDL. Common variants do not meaningfully predict response.
• UGT1A1 / UGT2B15 variants: can modestly affect ezetimibe glucuronidation and exposure but no clinically actionable threshold.
• LDLR / APOB / PCSK9 (FH genes): not pharmacogenomic for ezetimibe metabolism, but very relevant for whether Dylan needs it. 23andMe + Promethease coverage is good for major FH variants. Will be informative when results land June 2026.
• ABCG5 / ABCG8: governs biliary sterol efflux; rare loss-of-function = sitosterolemia (where ezetimibe is curative). Not a common SNP-level concern but worth noting.

For Dylan: only relevant if June bloodwork triggers a need. If so, cleanest path is GoodRx + Costco generic (~$5-10/mo) after a PCP visit + lipid panel. India-pharmacy backup exists at similar cost.

• Baseline (before starting):
  • Full lipid panel: total cholesterol, LDL-C, HDL, triglycerides
  • ApoB — the single most important atherogenic marker; more reliable than LDL-C
  • Lp(a) once in life — if elevated, changes the urgency calculation independently of ezetimibe
  • hsCRP
  • LFT: ALT, AST
  • HbA1c, fasting glucose (rule out metabolic phenotype)
  • Optional: serum sitosterol / campesterol (proxy for cholesterol absorption — high values suggest hyperabsorber phenotype, which predicts excellent ezetimibe response)
• During use (every 8-12 weeks initially, then 6-12 months):
  • LDL-C, ApoB, triglycerides, HDL — confirm target
  • LFT — every 8-12 weeks for first 6 months, then yearly
  • CK if any muscle complaint (especially on statin combo)
• Post-cycle (if discontinued): LDL-C will rise back to baseline within 4-8 weeks; reassess.